Renoprotective Effects of Combined Aliskiren and Valsartan in Progressive Diabetic Nephropathy in Rats

DOI:

https://doi.org/10.37285/ijpsn.2010.3.4.13

Authors

  • Vidya Sagar Jenugu
  • Hemanth Kumar Nyathani
  • Prashanth Srirangam
  • Krishna Mohan Chinnala

Abstract

 Renin angiotensin system plays a major role in the pathology of progressive Diabetic Nephropathy. In the present study, the renoprotective effects of low dose combined novel direct renin inhibitor-aliskiren and angiotensin II type 1 receptor blocker (ARB)-valsartan were estimated and compared with monotherapy in wistar rats.  Rats were divided into 5 groups: control, diabetic control, diabetic rats treated with aliskiren (10 mg/kg/day), valsartan (20 mg/kg/day) and combination of aliskiren and valsartan (5 mg/kg/day, 10mg/kg/day respectively). Clinical characteristics like proteinuria, serum creatinine and renal histopathological studies like glomerulosclrotic index, tubulointerstitial fibrosis were estimated and compared between all diabetic rats. Results showed that combination therapy of aliskiren and valsartan was more effective than the monotherapy in progressive diabetic nephropathy. 

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Renin-angiotensin system, Diabetic Nephropathy, Direct renin inhibitor, Aliskiren, Angiotensin II type 1 receptor blocker, Valsartan

Downloads

Published

2011-02-28

How to Cite

1.
Jenugu VS, Nyathani HK, Srirangam P, Chinnala KM. Renoprotective Effects of Combined Aliskiren and Valsartan in Progressive Diabetic Nephropathy in Rats. Scopus Indexed [Internet]. 2011 Feb. 28 [cited 2024 May 10];3(4):1276-8. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/546

Issue

Vol. 3 No. 4 (2010): January-March 2011

Section

Research Articles
Crossref
Scopus
Google Scholar
Europe PMC

References

Charles R. Craig, Robert E. Stitzel, Modern Pharmacology with Clinical Applications. Fifth Edition: 156, 213, 217.

Clark CJ, Lee D. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med. 332: 1210-1217(1995).

Cudworth AG, Bodansky HJ, West KM. Genetic and metabolic factors in relationship to the prevalence and severity of metabolic complications. Keen HJJ, ed. Complications of Diabetes. London, England; 1992.

D.J Kelly. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia. 50: 2398-2404 (2007).

Dominik N. Muller, Wolfgang Derer. Ralf Dechend. Aliskiren-mode of action and preclinical data. J Mol Med. 86: 659-662 (2008).

Eastman R, Siebert C, Harris M, Gorden P. Clinical review: implications of the Diabetes control and complications trial. J. Clin Endocrinol Metab 77: 1105-1107 (1993).

Fore W. Noninsulin-dependent diabetes mellitus-the prevention of complications. Med Clin North Am. 79: 287-298(1995).

Hans-Henrik Parving, M.D, D.M.S.C. Aliskiren combined with Losartan in Type2 Diabetes and Nephropathy. N Engl J Med. 23: 2433-2446 (2008).

Jennifer L. Wilkinson-Berka. Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2) 27 rat. Nephrol Dial Transplant. 16: 1343-1349 (2001).

Kelly DJ, Hepper C, Zhang Y, Jaworski K, Wilkinson-Berka JL, Gilbert RE. Protein kinase C β inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes. 52: 512–518 (2003).

Lehr HA, Mankoff DA, Corwin D, Santeusanio G, Gown AM. Application of Photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem. 45: 1559–1565 (1997).

Lehr HA, van der Loos CM, Teeling P, Gown AM. Complete chromogen separation and analysis in double immunohistochemical stains using Photoshop-based image analysis. J Histochem Cytochem. 47: 119–126 (1999).

Makino H, Phenotypic modulation of the mechanism reflected by contractile proteins in diabetes. Diabetes 45: 488-495(1996).

Mauer SM, Structural-functional relationships in diabetic nephropathy. J Clin Invest 74: 1143-1155(1984).

Michel Azizi, MD, PhD; Joël Ménard, MD. Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists. Circulation. 109:2492-2499 (2004).

Nathan D. Relation between metabolic control and long-term complications of diabetes. Kahn CR, ed. Joslin’s Diabetes. Philadelphia, Pa: Lea & Febiger; 1994

Parving H.H, Osterby R, Ritz E: Diabetic Nephropathy. The Kidney, edited by Brenner BM, Philadelphia, WB Saunders. P.1731(2000).

Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int. 51: 2-15 (1997).

Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med. 320: 1161-1165 (1989).

Stern M. Diabetes and cardiovascular disease - the “common soil” hypothesis. Diabetes 44:369-374 (1995).

Turner R. The U.K. Prospective Diabetes Study-A review. Diabetes Care. 21 (Suppl 3): C35-C38 (1998).

USRDS: The United States Renal Data System. AMJ Kidney Dis. 42 [Suppl]: 1-230(2003).

Wlodzimierz Buczko, Justyna M. Hermanowicz., Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacological Reports 60: 623–631(2008).